Results 21 to 30 of about 72,950 (205)

How we treat bleeding associated with direct oral anticoagulants [PDF]

open access: yes, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo   +4 more
core   +1 more source

Assessing operative delay and complications in hip fracture patients on anticoagulants and antiplatelets

open access: yesSAGE Open Medicine, 2023
Objectives: Hip fractures represent a prevalent geriatric cause of morbidity and mortality. The presence of multiple comorbidities requiring the use of an anticoagulant or antiplatelet medication adds complexity to management and influences outcomes ...
Asheesh R Elete   +4 more
doaj   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

open access: yes, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo   +4 more
core   +1 more source

Direct Oral Anticoagulants

open access: yesJACC: Cardiovascular Interventions, 2014
This chapter reviews the new direct oral anticoagulants—thrombin inhibitor and Xa inhibitors. The specific drugs are reviewed as well as the specific indications—prevention and treatment of deep venous thrombosis, stroke prevention in atrial fibrillation, and then acute coronary syndrome.
Levy, Jerrold H.   +3 more
openaire   +2 more sources

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]

open access: yes, 2015
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core   +1 more source

The risk of bleeding minimization with direct oral anticoagulants

open access: yesАтеротромбоз, 2021
This review is devoted to the safety issues of anticoagulant therapy prescribed for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Direct oral anticoagulants are considered worldwide in accordance with the guidelines
Т. N. Novikova
doaj   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Counsell, Carl   +2 more
core   +1 more source

The new way of Dabigatran reversal – Idarucizumab

open access: yesJournal of Education, Health and Sport, 2019
Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański   +3 more
doaj   +3 more sources

The new, direct, target-specific oral anticoagulants

open access: yesJournal of Applied Hematology, 2015
In recent years, numerous alternatives to VKAs have been developed, the first competitors to warfarin are the novel oral anticoagulants (NOAC) or better referred to as Direct Oral Anti-Coagulant (DOAC) or Target Specific Oral Anti-coagulant (TSOAC ...
Nevine A Kassim
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

open access: yes, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy